Company intelligence / Profile preview
Sable Therapeutics
New York, NY, USAsabletherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Sable Therapeutics has developed novel polycation nanomedicines—SBL‑001 and SBL‑002—that selectively target and reduce the volume of fat cells by up to 70%. These compounds are engineered for high selectivity and can serve as discrete drug delivery systems for additional anti-obesity agents such as GLP‑1 analogues. The company recently entered an exclusive worldwide licensing agreement with Columbia University to advance these assets from laboratory research into clinical development. No published human clinical results yet; programs are transitioning from preclinical to early-stage clinical evaluation
- Therapeutic areas
- EndocrinologyDermatology
- Modalities
- NanoparticleSmall molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Columbia UniversityShanghai Liuqiang Medical Technology Co. Ltd.Turret Capital Management
Beyond the preview
Go deeper on Sable Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sable Therapeutics.